^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK positive + ROS1 positive

    i
    Other names: ALK1, Activin A Receptor Like Type 1, Serine/Threonine-Protein Kinase Receptor R3, Activin A Receptor Type II-Like 1, TGF-B Superfamily Receptor Type I, Activin Receptor-Like Kinase 1, Activin A Receptor Type IL, ACVRLK1, TSR-I, SKR3, Activin A Receptor, Type II-Like Kinase 1, HHT2, ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1,
    Entrez ID:
    238; 6098
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India. (PubMed, JCO Glob Oncol)
    Our study findings suggest that the prices of ceritinib and crizotinib need to be reduced significantly to justify their value for inclusion in India's publicly financed health insurance scheme for treatment of patients with locally advanced/metastatic ALK- and ROS1-positive NSCLC, respectively.
    Journal • HEOR
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 fusion • ROS1 positive • ALK positive + ROS1 positive
    |
    Xalkori (crizotinib) • Zykadia (ceritinib)
    10ms
    Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy. (PubMed, Eur J Med Chem)
    There are no significant drug breakthroughs in solving the problem of drug-resistant mutations. In this review, we summarize the chemical structural features of several novel dual ALK/ROS1 inhibitors, their inhibitory effect on ALK and ROS1 kinases, and future treatment strategies for patients with ALK and ROS1 inhibitor-resistant mutations.
    Review • Journal
    |
    IR (Insulin receptor)
    |
    ALK positive • ALK mutation • ROS1 positive • ALK positive + ROS1 positive
    12ms
    Anaplastic lymphoma kinase (ALK) and ROS 1– positive advanced NSCLC: A real-world institutional experience. (ASCO 2023)
    First line therapy was crizotinib, chemotherapy followed by maintenance crizotinib, ceritinib, Alectinib in 40(77%), 4(7.7%), 6(11.5%) and 2(3.8%) patients respectively. ALK and ROS1 positivity was seen in 8.1% and 2.8% of advanced NSCLC patients. Majority of patients were never smokers. Opposite lung and bone were the most common site of metastases.
    Clinical • Real-world evidence • Real-world • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive • ALK positive + ROS1 positive • ALK-ROS1 fusion
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Zykadia (ceritinib)
    over1year
    First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. (PubMed, Eur J Cancer)
    TQ-B3139 was well-tolerated and exhibited promising anti-tumor activities in patients with ALK and ROS1 positive advanced NSCLC.
    P1 data • Clinical Trial,Phase I • Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK rearrangement • ALK mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement • ALK positive + ROS1 positive
    |
    envonalkib (TQ-B3139)
    over2years
    Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature. (PubMed, Anticancer Drugs)
    We think that this rate will increase a little more with the widespread use of NGS from now on. Showing that ALK and ROS1 are positive together, longer survivals can be obtained by choosing therapies that are responsive to both.
    Clinical • Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement • ROS1 mutation • ALK positive + ROS1 positive
    |
    Xalkori (crizotinib)
    3years
    Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. (PubMed, Ther Adv Med Oncol)
    Neither prior treatments with second-generation TKIs nor BM had a significant influence on PFS and OS. Our data from real-life practice demonstrate the efficacy of lorlatinib in mostly heavily pretreated patients, providing a clinically meaningful option for patients with resistance mutations not covered by other targeted therapies and those with BM or leptomeningeal carcinomatosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    TP53 mutation • ALK positive • ROS1 positive • ROS1 G2032R • ALK G1202R • ALK positive + ROS1 positive
    |
    Lorbrena (lorlatinib)